2025
SJR Q1
JCR Q2 · 4,5
OA
441 matched articles
SCIE
Journal detail
Biomedicines
- Publisher
- Multidisciplinary Digital Publishing Institute (MDPI)
- Country
- Switzerland · Western Europe
- Type
- journal
- ISSN
-
22279059
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,165
- Quartile Q1
- H-Index 108
- Cites/doc 4,74
- Docs (3y) 9.523
- Cites (3y) 46.921
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 4,5
- 5Y JIF 4,7
- JCI 0,77
WoS indexes
- SCIE
Subject classification
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q2 | 1,165 | 4,5 | 4,7 | 0,77 | Q2 | 108 |
| 2024 | Q1 | Q1 | 1,114 | 3,9 | 4,2 | 0,83 | Q2 | 85 |
| 2023 | Q1 | Q1 | 0,962 | 3,9 | 4,1 | 0,88 | Q2 | 85 |
| 2022 | Q1 | Q1 | 0,897 | 4,7 | 4,9 | 0,87 | Q2 | 85 |
| 2021 | Q1 | Q2 | 0,874 | 4,8 | 5,2 | 0,81 | Q2 | 85 |
| 2020 | Q1 | Q1 | 1,511 | 6,1 | 5,7 | 0,91 | Q2 | 85 |
| 2019 | Q1 | Q1 | 1,508 | 4,7 | — | 0,86 | Q2 | 85 |
| 2017 | — | — | — | — | — | — | — | 85 |
| 2016 | — | — | — | — | — | — | — | 85 |
| 2015 | — | — | — | — | — | — | — | 85 |
| 2014 | — | — | — | — | — | — | — | 85 |
| 2013 | — | — | — | — | — | — | — | 85 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q2 | 103/328 |
| 2025 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q2 | 59/191 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 90/356 |
| 2024 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q2 | 114/320 |
| 2024 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q2 | 65/195 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 88/352 |
| 2023 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q2 | 106/313 |
| 2023 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q2 | 65/189 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 85/354 |
| 2022 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q2 | 92/285 |
| 2022 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q2 | 54/136 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 68/278 |
| 2021 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q2 | 121/297 |
| 2021 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q2 | 62/139 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 87/279 |
| 2020 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q1 | Q2 | 65/295 |
| 2020 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 32/140 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 33/276 |
| 2019 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 30/139 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 36/271 |